The tariff classification of Quinapril HCL (CAS-82586-55-8) in bulk, from India
Issued October 17, 2008 by U.S. Customs and Border Protection.
Tariff classification
HTS codes: 2933.49.2600
Headings: 2933
Product description
Quinapril HCL is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension and congestive heart failure.
CBP rationale
The applicable subheading for the Quinapril HCL will be 2933.49.2600, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused: Other: Other: Drugs: Other.
Full text
N040175 October 17, 2008 CLA-2-29:OT:RR:E:NC:2:238 CATEGORY: Classification TARIFF NO.: 2933.49.2600 Ms. Wendy Zamor Matrix Laboratories Inc. 76 South Orange Ave. Suite 301 South Orange, NJ 07079 RE: The tariff classification of Quinapril HCL (CAS-82586-55-8) in bulk, from India Dear Ms. Zamor: In your letter dated October 1, 2008, you requested a tariff classification ruling. Quinapril HCL is an angiotensin converting enzyme (ACE) inhibitor used in the treatment of hypertension and congestive heart failure. The applicable subheading for the Quinapril HCL will be 2933.49.2600, Harmonized Tariff Schedule of the United States (HTSUS), which provides for “Heterocyclic compounds with nitrogen hetero-atom(s) only: Compounds containing in the structure a quinoline or isoquinoline ring-system (whether or not hydrogenated), not further fused: Other: Other: Drugs: Other.” Pursuant to General Note 13, HTSUS, the rate of duty will be free. Duty rates are provided for your convenience and are subject to change. The text of the most recent HTSUS and the accompanying duty rates are provided on World Wide Web at http://www.usitc.gov/tata/hts/. This merchandise may be subject to the Federal Food, Drug, and Cosmetic Act and/or The Public Health Security and Bioterrorism Preparedness and Response Act of 2002 (The Bioterrorism Act), which are administered by the U.S. Food and Drug Administration (FDA). Information on the Federal Food, Drug, and Cosmetic Act, as well as The Bioterrorism Act, can be obtained by calling the FDA at 1-888-463-6332, or by visiting their website at www.fda.gov. This ruling is being issued under the provisions of Part 177 of the Customs Regulations (19 C.F.R. 177). A copy of the ruling or the control number indicated above should be provided with the entry documents filed at the time this merchandise is imported. If you have any questions regarding the ruling, contact National Import Specialist Harvey Kuperstein at (646) 733-3033. Sincerely, Robert B. Swierupski Director National Commodity Specialist Division
More rulings on the same tariff codes
The tariff classification of Lenvatinib Mesylate (CAS No. 857890-39-2) in bulk powder form, from Italy
The tariff classification of Lenvatinib Mesylate (CAS No. 857890-39-2) in bulk form, from India
The tariff classification of Cabozantinib (CAS No. 849217-68-1) in bulk powder form, from Finland
The tariff classification of Besifloxacin Hydrochloride (CAS No. 405165-61-9) in bulk form, from India
The tariff classification of Solifenacin Succinate (CAS 242478-38-2), in bulk powder form, from Spain
The tariff classification of Cabozantinib s-Malate (CAS-1140909-48-3), imported in bulk form and in dosage form
The tariff classification of Moxifloxacin Hydrochloride (CAS-186826-86-8) in bulk form, from Italy
The tariff classification of Butorphanol Tartrate (CAS- 58786-99-5) imported in bulk form, from India
The tariff classification of Cisatracurium Besylate (CAS# 96946-42-8) in bulk form, from Italy
The tariff classification of Investigational New Drug VX-770 (N-(2,4-Di-tert-butyl-5-hydroxyphenyl)-1,4-dihydro-4-oxoquinoline-3-carboxamide) in bulk and in dosage forms, from Portugal and the United Kingdom
Searching CBP rulings the smart way
TariffLens semantically searches all 200,000+ CBP rulings, surfaces the ones that actually match your product, and builds defensible classifications backed by ruling citations.
Book a demo →